Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Abstract Text:

Abstract Background: The Metabolic Syndrome (MS) confers an increased risk for diabetes and cardiovascular disease. We previously showed that simvastatin has concomitant benefits in reducing low-density lipoprotein (LDL)-cholesterol and inflammation in MS subjects. The levels of plasminogen activator inhibitor 1(PAI-1), soluble P-selectin (sP-selectin), and soluble CD40 ligand (sCD40L) play an important role in the development and progression of atherosclerosis. Their levels are increased in the MS. The current study was to investigate the effects of simvastatin on PAI-1, sP-selectin, and sCD40 ligand. Methods: Fifty subjects with MS were randomized into either placebo or simvastatin (40 mg/day) group for 8 weeks. Blood samples were obtained at baseline and at the end of the study. PAI-1 activity and sP-selectin and sCD40L levels were measured by enzyme-linked immunosorbent assay (ELISA). Results: There was no baseline difference in any of the parameters studied. Compared to baseline, simvastatin significantly reduced (P < 0.05) the circulating PAI-1 activity (24.3 +/- 5.2 IU/mL at baseline vs. 21.4 +/- 3.9 IU/mL after 8 weeks of treatment). Simvastatin did not alter (P < 0.05) the levels of sP-selectin (111.4 +/- 35.9 ng/mL at baseline vs. 118.5 +/- 71.2 ng/mL after 8 weeks) or sCD40L (2.0 +/- 1.6 ng/mL at baseline vs. 1.5 +/- 1.0 ng/mL after 8 weeks). Conclusion: Our data indicate that simvastatin therapy has significant effects on the fibrinolytic system in MS subjects as evidenced in a reduction in PAI-1 activity.

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Metabolic syndrome and related disorders

VOLUME: 6

Page Numbers: 149-52

Journal Abbreviation:

ISSN: 1557-8518

DAY: 30

MONTH: 05

YEAR: 2008

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101150318

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.

AFFILIATION: Laboratory for Atherosclerosis and Metabolic Research, Department of Pathology and Laboratory Medicine, University of California, Davis, Medical Center, Sacramento, CA.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Metab Syndr Relat Disord

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome Related Publications

• A dose-response study on the effects of purified lycopene supplementation on biomarkers of oxidative stress.
• Adiponectin decreases C-reactive protein synthesis and secretion from endothelial cells: evidence for an adipose tissue-vascular loop.
• C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling.
• CRP and adiponectin and its oligomers in the metabolic syndrome: evaluation of new laboratory-based biomarkers.
• Contemporary scientific insights: role of biomarkers of inflammation in cardiovascular disease/atherosclerosis.
• Detection by immunofixation of M proteins in hypogammaglobulinemic patients with normal serum protein electrophoresis results.
• Direct demonstration of an antiinflammatory effect of simvastatin in subjects with the metabolic syndrome.
• Editor's Perspective on Metabolic Syndrome for 2008.
• Editorial.
• Effect of high-dose {alpha}-tocopherol supplementation on biomarkers of oxidative stress and inflammation and carotid atherosclerosis in patients with coronary artery disease.
• Gamma-tocopherol supplementation alone and in combination with alpha-tocopherol alters biomarkers of oxidative stress and inflammation in subjects with metabolic syndrome.
• High-dose alpha-tocopherol therapy does not affect HDL subfractions in patients with coronary artery disease on statin therapy.
• High-fat, energy-dense, fast-food-style breakfast results in an increase in oxidative stress in metabolic syndrome.
• Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats.
• Increased Toll-Like Receptor (TLR) 2 and TLR4 Expression in Monocytes from Patients with Type 1 Diabetes: Further Evidence of a Proinflammatory State.
• Oxidative stress and atherosclerosis.
• RRR-alpha-tocopheryl acetate supplementation at pharmacologic doses decreases low-density-lipoprotein oxidative susceptibility but not protein glycation in patients with diabetes mellitus.
• Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome.
• Simvastatin reduces circulating plasminogen activator inhibitor 1 activity in volunteers with the metabolic syndrome.
• Statins and biomarkers of inflammation.
• The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells.
• The effect of weight loss and dietary fatty acids on inflammation.
• Validation of the circulating monocyte being representative of the cholesterol-loaded macrophage: biomediator activity.